News
- Author:
- Susan London
Publish date: February 26, 2020
SAN FRANCISCO – Intravesical gene therapy produced durable responses in patients with non–muscle invasive bladder cancer that did not respond to Ba...
News
- Author:
- Susan London
Publish date: February 22, 2020
SAN FRANCISCO – The risk of second progression-free survival events was about one-third lower for patients who initially received apalutamide compa...
News
- Author:
- Susan London
Publish date: February 22, 2020
SAN FRANCISCO – Findings of the SEMITEP trial suggest that early FDG-PET identifies the two-thirds of men with highly chemosensitive low-volume met...
News
- Author:
- Susan London
Publish date: February 21, 2020
SAN FRANCISCO – More than half of patients in the RADVAX RCC trial had a response in nonirradiated lesions, but the prespecified threshold for effi...
News
- Author:
- Susan London
Publish date: February 20, 2020
SAN FRANCISCO - A multiomics test detected stage I and II colorectal cancer with 94% sensitivity and specificity, outperforming a fecal immunochemi...
News
- Author:
- Susan London
Publish date: February 18, 2020
SAN FRANCISCO – An 8-year update of the CHHiP trial confirms that hypofractionated radiotherapy yields a noninferior rate of freedom from biochemic...
News
- Author:
- Susan London
Publish date: February 18, 2020
SAN FRANCISCO – Adding docetaxel to androgen deprivation therapy significantly improved overall survival among men with the luminal B subtype of me...
News
- Author:
- Susan London
Publish date: February 4, 2020
SAN FRANCISCO – A multiomics test detected stage I and II colorectal cancer with 94% sensitivity and specificity, outperforming a fecal immunochemi...
News
- Author:
- Susan London
Publish date: February 3, 2020
SAN FRANCISCO – A trial pitting avelumab maintenance against continued chemotherapy was negative, but a flipping of the survival curves during foll...
News
- Author:
- Susan London
Publish date: January 29, 2020
SAN FRANCISCO – At a median follow-up of almost 20 months, combination nivolumab and ipilimumab remained highly active as first-line therapy for MS...
News
- Author:
- Susan London
Publish date: January 28, 2020
SAN FRANCISCO – In the first randomized trial to report on this practice, median overall survival was about 2 years regardless of whether or not pa...
News
- Author:
- Susan London
Publish date: January 27, 2020
SAN FRANCISCO – About two-thirds of patients had a response with combination cisplatin and gemcitabine, and adding the PARP inhibitor veliparib did...
News
- Author:
- Susan London
Publish date: January 27, 2020
SAN FRANCISCO – Patients with colorectal cancer aged 40 years or younger who lived in areas having low income and low educational attainment, or in...
News
- Author:
- Susan London
Publish date: January 24, 2020
The Circulating Cell-free Genome Atlas (CCGA) study finds that a multicancer assay using targeted methylation sequencing of plasma cell-free DNA ha...
News
- Author:
- Susan London
Publish date: December 27, 2019
Addition of both trastuzumab and pertuzumab to neoadjuvant chemoradiotherapy for resectable HER2-positive esophageal adenocarcinoma is feasible and...
